长期治疗伊托利祖马布对于中度至重度牛皮的患者是安全有效的:扩展访问计划的结果
Leopoldina Falcón Lincheta1, Yaimarelis Saumell Nápoles2, Olaine R Gray Lovio3
1"Dr. Carlos J. Finlay" Hospital, Havana, Cuba.
International immunopharmacology
|May 17, 2024
概括
伊托利祖马布在一项临床研究中有效治疗中度至重度的斑块性牛皮. 该药物在52周内表现出持续的疗效和安全性,即使在停止治疗后也能带来持久的益处.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 斑块性牛皮是一种慢性自身免疫性疾病,影响生活质量.
- 现有的全身疗法在有效性和耐受性方面存在局限性.
- CD6-ALCAM通路是牛皮的潜在治疗标.
研究的目的:
- 评估伊托利祖马布在中度至重度斑块性牛皮患者的安全性和疗效.
- 评估伊托利祖马布治疗和随访的长期结果.
- 为了确定伊托利祖马布在牛皮治疗中的最佳剂量.
主要方法:
- 在古巴的一项扩展访问计划 (EAP) 临床研究.
- 招募了84名先前治疗失败或不耐受症的患者.
- 伊托利祖马布在0.4或1.6毫克/公斤剂量中服用了52周,随访时间为24周.
主要成果:
- 伊托利祖马布单一治疗在52周内显示出显著的安全性和有效性.
- 80%的患者在诱导结束时达到PASI75,持续到第52周.
- 三分之二的患者在治疗后24周保持PASI≥75.
- 发现1.6mg/kg剂量是最有效的.
结论:
- 伊托利祖马布是适度至严重斑块性牛皮的安全有效治疗方法.
- 用伊托利祖马布向CD6-ALCAM通路提供了一个有前途的治疗策略.
- 伊托利祖马布 (itolizumab) 是牛皮治疗武器库中一个有价值的补充.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Ulcerative Colitis in IBD
136
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
136


